Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis--new pathways to epitope spreading.

Hospital Pharmacy, Malmö University Hospital, Malmö, Sweden.
Clinical and experimental rheumatology (Impact Factor: 2.97). 01/2006; 24(1):12-8.
Source: PubMed

ABSTRACT The findings of the involvement of tissue transglutaminase (tTg) in the pathogenesis of coeliac disease (CD) have stimulated progress in the field of auto-immune diseases. Another calcium-dependent cysteine enzyme, peptidylarginine deiminase type 4 (PAD4), seems to be involved in the pathogenesis of rheumatoid arthritis (RA). There are obvious similarities between Tgs and PADs.
Using enzyme-linked immuno-sorbent assays, we have measured the occurrence of antibodies against guinea pig (gp) and human recombinant (hr) tTg, PAD and citrulline in 59 controls and 184 RA-patients, of whom 71 were treated with methotrexate (mtx).
In addition to the expected antibodies against citrulline (62%), sera from the 113 RA-patients without mtx treatment contained significantly increased frequencies of IgG anti-PAD (35%), IgA anti-gp-tTg (34%), IgA anti-hr tTg (20%), IgG anti-gp-tTg (13%) and IgA anti-hr-FXIII (15%) compared to controls. In sera from the mtx-treated RA-patients the expression of antibodies was reduced. In patients not treated with methotrexate there was a statistically significant correlation between, on one hand, IgG anti-PAD and on the other hand, IgG anti-citrulline, IgA anti-gp-tTg, IgA anti-hr-tTg, IgG anti-gp-tTg, IgG anti-hr-tTg, or IgA anti-hr-FXIII. In the mtx-treated group these correlations were less pronounced.
In addition to the expected antibodies against citrulline, sera from RA-patients contained antibodies against PAD and against Tgs of at least two kinds, indicating that the specificity for anti-tTg in CD is far from complete. Most of the patients displayed more than one antibody, a possible indication of epitope spreading. MTX-treatment reduced the expression of antibodies.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease causing articular cartilage and bone destruction. Since irreversible joint destruction can be prevented by intervention at the early stages of disease, early diagnosis of RA is important. In this study, we identified new autoantibodies in the sera of patients with early (less than one year) RA. We screened the sera of 20 RA patients with a disease duration of less than one year, 19 RA patients with a disease duration of more than five years and 23 controls on 8268 human protein arrays. We confirmed the validity of protein array detection by ELISA assays. We then performed epitope mapping with overlapping 15mers to analyze RA sera reactivity. WIBG (within BGCN homolog (Drosophila)), GABARAPL2 (GABA(A) receptor associated protein like 2) and ZNF706 (zinc finger protein 706) proteins are preferentially recognized by autoantibodies from early RA patients. Of interest, autoantibodies to WIBG are very specific for early RA. Indeed, 33% of early RA patients' sera recognize WIBG versus 5% of RA patients with disease duration more than 5 years and 2% of controls. We identified three linear peptides on WIBG GABARAPL2 and ZNF706 that are preferentially recognized by sera of early RA patients. We identified new autoantibodies associated with RA with disease duration less than one year. These autoantibodies could be used as diagnosis markers in RA patients.
    Arthritis Research & Therapy 07/2013; 15(4):R78. DOI:10.1186/ar4255 · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Importance of the field: Biomarkers are emerging as vital tools for early diagnosis, prognostication and disease management in chronic diseases, including rheumatoid arthritis (RA). Areas covered in this review: This review discusses diagnostic, prognostic and theranostic biomarker candidates for RA that are being studied at present. What the reader will gain: The reader will gain a better understanding of the different classes of markers being proposed as potential biomarkers for RA, and how they compare with each other. Take home message: At present, several molecules are showing varying degrees of promise as potential biomarkers in RA. These include serum rheumatoid factors and anti-cyclic citrullinated protein antibodies, a couple of acute phase proteins and pro-inflammatory cytokines expressed in the serum and/or diseased joints, notably IL-1, IL-6, TNF-α, MCP-1 and MIP-α, as well as molecules released by damaged synovial tissue, cartilage and bone. Continuing proteomic and metabolomic efforts are rapidly expanding this repertoire of potential biomarker candidates. Large-scale longitudinal trials are clearly needed where several biomarker candidates can be assessed in parallel, relative to current yardsticks. The ultimate goal is to distill out a subset of informative biomarkers, presumably representing distinct pathogenic pathways, which will enable the rheumatologist to prognosticate, predict and actively manage the disease course in RA.
    Expert Opinion on Medical Diagnostics 07/2010; 4(4):293-305. DOI:10.1517/17530059.2010.492828
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of anticitrullinated protein antibodies in the last century has changed this and other posttranslational modifications (PTM) relevant to RA have since been described. Such PTM introduce neoepitopes in proteins that can generate novel autoantibody specificities. The recent recognition of these novel specificities in RA provides a unique opportunity to understand human B-cell development in vivo. In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation. With the advancement of research methodologies it should be expected that other autoantibodies against PTM proteins could be discovered in patients with autoimmune diseases. Many of such autoantibodies may provide significant biomarker potential.
    Mediators of Inflammation 01/2014; 2014:492873. DOI:10.1155/2014/492873 · 2.42 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014